Advances in prostate cancer imaging [version 1; referees: 3 approved]
Many exciting advances in medical imaging have been made in recent years that will alter the way we diagnose, stage, and treat patients with prostate cancer. Multiparametric magnetic resonance imaging (MRI) is emerging as the main modality for prostate cancer imaging. Contrast-enhanced ultrasound an...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
F1000 Research Ltd
2018-08-01
|
Series: | F1000Research |
Online Access: | https://f1000research.com/articles/7-1337/v1 |
id |
doaj-ff45b5c4a0af42a283774a9e75555a30 |
---|---|
record_format |
Article |
spelling |
doaj-ff45b5c4a0af42a283774a9e75555a302020-11-25T03:51:03ZengF1000 Research LtdF1000Research2046-14022018-08-01710.12688/f1000research.14498.115783Advances in prostate cancer imaging [version 1; referees: 3 approved]Matthew R. Tangel0Ardeshir R. Rastinehad1Department of Radiology, Mount Sinai Health System, New York, NY, 10003, USADepartment of Interventional Radiology, Mount Sinai Health System, New York, NY, 10003, USAMany exciting advances in medical imaging have been made in recent years that will alter the way we diagnose, stage, and treat patients with prostate cancer. Multiparametric magnetic resonance imaging (MRI) is emerging as the main modality for prostate cancer imaging. Contrast-enhanced ultrasound and shear wave elastography may be strong alternatives in patients who cannot undergo MRI. Prostate-specific membrane antigen-directed positron emission tomography/computed tomography has proven to be valuable in the primary staging of high-risk disease and for detecting disease in patients with biochemical recurrence. As more studies continue to emerge, it is becoming clear that the standard algorithm for diagnosing and staging prostate cancer will undergo significant changes in the near future.https://f1000research.com/articles/7-1337/v1 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Matthew R. Tangel Ardeshir R. Rastinehad |
spellingShingle |
Matthew R. Tangel Ardeshir R. Rastinehad Advances in prostate cancer imaging [version 1; referees: 3 approved] F1000Research |
author_facet |
Matthew R. Tangel Ardeshir R. Rastinehad |
author_sort |
Matthew R. Tangel |
title |
Advances in prostate cancer imaging [version 1; referees: 3 approved] |
title_short |
Advances in prostate cancer imaging [version 1; referees: 3 approved] |
title_full |
Advances in prostate cancer imaging [version 1; referees: 3 approved] |
title_fullStr |
Advances in prostate cancer imaging [version 1; referees: 3 approved] |
title_full_unstemmed |
Advances in prostate cancer imaging [version 1; referees: 3 approved] |
title_sort |
advances in prostate cancer imaging [version 1; referees: 3 approved] |
publisher |
F1000 Research Ltd |
series |
F1000Research |
issn |
2046-1402 |
publishDate |
2018-08-01 |
description |
Many exciting advances in medical imaging have been made in recent years that will alter the way we diagnose, stage, and treat patients with prostate cancer. Multiparametric magnetic resonance imaging (MRI) is emerging as the main modality for prostate cancer imaging. Contrast-enhanced ultrasound and shear wave elastography may be strong alternatives in patients who cannot undergo MRI. Prostate-specific membrane antigen-directed positron emission tomography/computed tomography has proven to be valuable in the primary staging of high-risk disease and for detecting disease in patients with biochemical recurrence. As more studies continue to emerge, it is becoming clear that the standard algorithm for diagnosing and staging prostate cancer will undergo significant changes in the near future. |
url |
https://f1000research.com/articles/7-1337/v1 |
work_keys_str_mv |
AT matthewrtangel advancesinprostatecancerimagingversion1referees3approved AT ardeshirrrastinehad advancesinprostatecancerimagingversion1referees3approved |
_version_ |
1724489092765319168 |